Plain-English translation of NCT07615426 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Schizophrenia research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can safely help people with schizophrenia when used alongside their current antipsychotic medication. The study wants to understand whether this treatment is feasible to use in real-world settings and whether it is well-tolerated by patients. Half of the participants will receive the medication while the other half will receive a placebo (a pill with no active ingredient) to fairly compare how well the treatment works.
Schizophrenia is a serious mental health condition, and while current antipsychotic medications help many people, researchers are exploring additional treatments that might work better when combined with existing medications. This study is checking whether this new treatment could be a safe and helpful add-on option.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will be randomly assigned to either receive the new medication or a placebo while continuing your regular antipsychotic treatment. You will attend study visits where researchers will check your safety, how well you tolerate the treatment, and collect blood samples to confirm you are taking your regular medication. The study is designed to be double-blind, meaning neither you nor the research team will know which group you're in, which helps keep the results fair and unbiased.
AI-generated summary from trial data ยท Oct 3, 2026 ยท Not medical advice
United States